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Supplementary Figure 1 
Histograms of imputation r2 (a) Variants with MAF >=0.05 (b) Variants with MAF <0.05. 
 
 
Supplementary Figure 2 
Quantile-quantile plots of the GWAS meta-analyses analyses of GWAS by geographical 
region Europe, South America and North America (adjusted by age, sex and region 
eigenvectors) (a) Overall oral cavity and pharynx cancer (λ=1.06), (b) oral cancer 







Supplementary Figure 3 
Quantile-quantile plots of by region GWAS. Top panel: overall oral and pharyngeal 
cancer; middle panel: oral cancer; bottom panel:  oropharyngeal cancer. From left to 
right Europe, North America and South America. All analyses adjusted by age, sex and 
eigenvectors.   
Supplementary Figure 4 
Sequence chromatogram of rs201982221 (10q26.13). a. Example of wild type insertion. 
b. Example of homozygous deletion. The deletion start corresponds to nucleotide 105 in 







Supplementary Figure 5 
Regional association plot at 10q26.13. Chromosome positions (x-axis) and -log10 P-
value (y-axis) for oral cavity and pharynx cancer. LD information and recombination 
rates from 1000 Genomes Project November 2014 release (EUR population). Genome 
coordinates according to NCBI genome build 37 (Hg19). Genotyped and imputed 














Supplementary Figure 6 
Regional association plot at 11p15.4. Chromosome positions (x-axis) and -log10 P-
value (y-axis) for oral cavity and pharynx cancer. LD information and recombination 
rates from 1000 Genomes Project November 2014 release (EUR population). Genome 
coordinates according to NCBI genome build 37 (Hg19). Genotyped and imputed 





















Supplementary Figure 7 
Regional association plot at 2p23.3, Chromosome positions (x-axis) and -log10 P-value 
(y-axis) for oral cancer LD information and recombination rates from 1000 Genomes 
Project November 2014 release (EUR population). Genome coordinates according to 
NCBI genome build 37 (Hg19). Genotyped and imputed variants colored according to 









Supplementary Figure 8 
Regional association plots at 5p15.33. (a) rs10462706 (b) rs467095 (2nd strongest 
association). Chromosome positions (x-axis) and -log10 P-value (y-axis) plotted for oral 
cancer. LD information and recombination rates from 1000 Genomes Project November 
2014 release (EUR population). Genome coordinates according to NCBI genome build 
37 (Hg19). Genotyped and imputed variants colored according to their LD with the 






Supplementary Figure 9 
Forest plot of odds ratios for oral cancer association and 5q15.3 rs467095 CLPTM1, 












Supplementary Figure 10 
Regional association plots. a) rs8181047 at 9p21.3, b) rs928674 at 9q34.12. 
Chromosome positions (x-axis) and the -log10 P-values (y-axis) for oral cancer. LD and 
recombination rates from 1000 Genomes Project November 2014 release (EUR 
population). Genome coordinates according to NCBI genome build 37 (Hg19). The plots 
show genotyped and imputed variants colored according to their LD with the labeled 








Supplementary Figure 11 
Regional association plot at 6p21.32. Chromosome positions (x-axis) and -log10 P-
values (y-axis) for combined oral and pharyngeal cancer. LD and recombination rates 
from 1000 Genomes Project November 2014 release (EUR population). Genome 
coordinates according to NCBI genome build 37 (Hg19). Genotyped and imputed 











Supplementary Figure 12  
Genotype cluster plots of top loci 
(a)2p23 rs1919126; (b) 9p21.3, rs8181047; (c) 6p21.32, rs3134995; (d) 5p15.3, rs467095; 
(e)9q34, rs199717881/chr9_133953882_A_C; (f)10q26, 
rs201982221/chr10_126157446_CAG_INDEL; (f)11p15, rs1453414/chr11_5829084_G_T; 
(h)5p14, rs79767424/chr5_19108690_G_T, (SNP not validated by Taqman). In tables, Hardy 
Weinberg P-value (controls) and percent of genotypes with no call (P_MISS).  
 
   a                                                                   b 

























e                                          f 
g                                           h 
Supplementary Figure 13 
Principal Components Analyses (PCA) of all the study participants and within 
regions. Principal component 1 is displayed in the x-axis and principal component 2 in 










Supplementary Figure 14 
Principal Components Analyses (PCA) within epidemiological study. Principal 
component 1 is displayed in the x-axis and principal component 2 in the y-axis. Blue 
dots are cases and black dots are controls.  
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Supplementary Table 2  
Individual exclusions in HNC OncoArray quality control (QC) 
Exclusion criteria Cases Controls Total 
Initial dataset 6289 6818 13107 
Low success rates (<95%) 0 15 15 
Sex mismatch 18 34 52 
Outlier heterozygosity 39 22 61 
Expected duplicate 36 67 103 
Unexpected duplicates 32 42 74 
Unexpected Relatives IBD >0.3 4 40 44 
By Geographic Region QC 
Europe PCA outliers 17 2 19 
North America PCA outliers 108 4 112 
South America PCA outliers 1 7 8 
Included in analysis 
  
  
Europe 2499 2928 5427 
North America 2549 2522 5071 
South America 986 1135 2121 







Supplementary Table 3 
Genetic ancestrya of individuals by region 
  >70% CEU >70%YRI >30 admix total 
Region n % n % 
 
%   
Europe 5425 100 0 0 2 0.04 5427 
North America 4671 92 298 5.9 102 2 5071 
South America 1340 63 63 3 718 34 2121 
Total 11436 90.6 361 2.9 822 6.5 12619 
a 
Analysis in STRUCTURE 2.3.4 software 
 
 















Supplementary Table 12 
Expression Quantitative Trait Loci (eQTL)1 for lead SNPs within each associated region 
(P<5x10-8) 
Region rs Gene Functional 
class 





2p23.3 rs6547741 GPN1 intronic A/G Esophagus - 
Mucosa 
AC074117.10 0.23 0.000018 
      Muscle - 
Skeletal 
SNX17 0.33 8.60E-15 
      Spleen FNDC4 -0.69 3.60E-12 
      Spleen GCKR -0.81 9.50E-11 
      Skin - Sun 
Exposed 
(Lower leg) 
NRBP1 0.29 6.50E-07 
      Lung NRBP1 0.22 0.000014 
      Cells - 
Transformed 
fibroblasts 
AC074117.10 0.23 0.000035 
5p15.33 rs467095 CLPTM1L intronic G/A Esophagus - 
Mucosa 
TERT -0.3 1.70E-06 
9q34.12 rs928674 LAMC3 intronic G/A Esophagus - 
Mucosa 
AIF1L 0.25 4.2E-06 
11p15.4 rs1453414 OR52N2/ 
TRIM5 



















 Supplementary Table 13 


















ol OR P 
 Overall oral and pharynx cancer 
4q23 rs1229984 0.50 1.0E-09 0.75 1.4E-02 0.43 3.8E-05 0.03 0.06 0.58 7.2E-13 
5p14.3 rs79767424 0.42 2.7E-06 0.66 1.7E-02 0.63 1.2E-01 0.01 0.02 0.55 2.3E-07 
6p21.32 rs3828805 1.39 6.2E-09 1.29 7E-07 1.11 3E-01 0.75 0.72 1.30 9.8E-14 
11p15.4 rs1453414 1.22 1.5E-04 1.21 3.5E-04 1.15 1.5E-01 0.22 0.19 1.21 7.4E-08 
10q26.1 rs201982221 1.87 1.3E-06 1.51 1.5E-03 1.33 3.0E-01 0.03 0.02 1.64 1.2E-08 
Oral cancer 
         
  
2p23.3 rs6547741 0.84 6.7E-04 0.81 8.9E-05 0.97 7.8E-01 0.50 0.54 1.23 2.5E-08 
5p15.33 rs10462706 0.75 1.7E-04 0.74 1.3E-04 0.64 2.3E-03 0.12 0.16 0.73 1.1E-09 
5p15.33 rs467095 1.19 6.9E-04 1.26 1.7E-05 1.25 2.2E-02 0.49 0.44 1.22 3.9E-09 
9p21.3 rs8181047 1.18 2.3E-03 1.26 5.6E-05 1.34 9.6E-03 0.31 0.26 1.23 2.5E-08 
9q34.12 rs928674 1.30 9.2E-04 1.33 4.2E-04 1.22 2.2E-01 0.13 0.11 1.30 6.8E-07 
Oropharyngeal cancer 


















 Supplementary Table 14 
Validation of risk loci by TaqMan genotyping in ~ 700 individuals 
  
     
Meta-analysis results 














rs9270911 6p21.3 HLA-DRB1 758 100.0 Imputed 1.16 3.50E-07 overall 





/TRIM5 759 99.9 Genotyped 1.17 6.95E-06 overall 
rs1919126 2p23.3 C2orf16 677 100.0 Genotyped 1.19 1.28E-07 OC 
rs467095 5p15.3 CLPTM1L 747 100.0 Genotyped 1.20 1.77E-08 OC 
rs3130614 6p21.3 MICB 684 99.7 Imputed 1.37 2.49E-07 OC 
rs3731239 9p21.3 CDKN2A 736 100.0 Genotyped 1.21 1.22E-08 OC 
rs73658919 9q34.1 LAMC3 725 99.2 Imputed 1.33 3.96E-08 OC 
rs12910284 15q21. LOC105370811 762 99.9 Imputed 1.19 4.28E-07 OC 
rs2398180 15q26. NR2F2-AS1 689 93.8 Imputed 1.20 2.77E-07 OC 
rs1961637 2q36.1 
 
665 100.0 Imputed 1.21 3.49E-07 OPC 
rs12524487 6p21.3 HLA-S 791 97.1 Genotyped 0.66 1.68E-07 OPC 
a
 Number of shared genotypes between array/imputed and TaqMan genotyped samples  
b 
Concordance between array genotyped or imputed variants and TaqMan genotypes in a subset of 
individuals from ARCAGE, IARC Latin America, EPIC, and IARC oral CA study. 
c
 Genotyped in the OncoArray or imputed variant 
d
Overall=oral and pharynx cancer, OC=oral cancer, OPC= oropharyngeal cancer 
e













 Supplementary Table 15 
Unconditional and conditional analyses (meta-analysis from 3 regions) for overall oral 
and pharynx cancer variants (P<5x10-8) at 4q23, conditioning was performed on the 
lead SNP rs1229984. Analyses adjusted by age, sex and eigenvectors. 
a SNP position according to NCBI genome build 37 (Hg19) 























allele ORb P ORb P 
rs1229984 4:100239319 A G 0.5587 2.29E-15 
 
  
rs116203444 4:100068114 C T 0.5936 2.51E-07 0.91 0.44 
rs138495951 4:100249726 A G 0.5185 1.75E-09 0.91 0.50 
rs141973904 4:100262242 T C 0.5188 1.98E-09 0.90 0.47 
rs145452708 4:100248642 C G 0.5181 1.64E-09 0.91 0.50 
rs146788033 4:99941138 G A 0.5522 5.61E-08 0.90 0.42 
Supplementary Table 16 
Oral and oropharynx cancer results for previously identified loci in the upper 
aereodigestive tract GWAS (McKay et al 2011) 
OC  OncoArray results* 




















































































*Results for non-overlapping individuals between this study and UADT GWAS; OC=Oral 
cancer; OPC= Oral Cavity Cancer; EA=effect allele; OA=other allele. 
**Note: rs1494961, rs1789924 and rs4767364 were significantly associated with all 













Supplementary Table 17 
Unconditional and conditional analyses (meta-analysis from 3 regions) for overall oral 
and pharynx cancer variants (P<5x10-6) at 11p15, conditioning on the lead SNP 
rs1453414. Analyses adjusted by age, sex and eigenvectors. 












rs1453414 11:5829084 C A 1.19 4.78E-08 
 
  
rs10838607 11:5778538 C T 1.18 4.73E-06 1.02 0.80 
rs11038937 11:5777248 C T 1.17 4.96E-06 1.02 0.81 
rs11038939 11:5777395 A G 1.18 4.88E-06 1.02 0.81 
rs11038940 11:5777739 C T 1.18 4.82E-06 1.02 0.80 
rs11038942 11:5778010 G A 1.18 4.77E-06 1.02 0.80 
rs11038944 11:5778930 T C 1.18 4.71E-06 1.02 0.80 
rs11038945 11:5779431 G A 1.18 4.66E-06 1.02 0.79 
rs11038946 11:5779859 T C 1.18 4.27E-06 1.02 0.77 
rs11038949 11:5780198 T A 1.18 4.16E-06 1.02 0.76 
rs11038950 11:5780334 T C 1.18 3.74E-06 1.02 0.73 
rs11038951 11:5780343 C G 1.18 3.63E-06 1.02 0.72 
rs11038952 11:5780354 C T 1.18 3.8E-06 1.02 0.73 
rs11038960 11:5780740 C T 1.18 4.04E-06 1.02 0.76 
rs11826964 11:5775269 C T 1.18 4.23E-06 1.02 0.75 
rs11828490 11:5775148 A G 1.18 4.07E-06 1.02 0.74 
rs12362742 11:5774732 G C 1.17 6.08E-06 1.03 0.67 
rs12362750 11:5774765 T C 1.18 2.92E-06 1.03 0.64 
rs12363545 11:5777096 C T 1.17 4.94E-06 1.02 0.81 
rs12364223 11:5774253 T A 1.18 2.73E-06 1.03 0.62 
rs12364265 11:5774653 C A 1.18 3.12E-06 1.03 0.66 
rs12364563 11:5774429 C T 1.18 2.92E-06 1.03 0.64 
rs12364723 11:5775788 G A 1.18 4.33E-06 1.02 0.76 
rs12365564 11:5774436 C G 1.18 2.95E-06 1.03 0.64 
rs12365568 11:5774455 A G 1.18 2.97E-06 1.03 0.64 
rs12793267 11:5774025 T C 1.18 2.79E-06 1.03 0.62 
rs1498557 11:5773051 T A 1.18 2.2E-06 1.05 0.39 
rs1498558 11:5772818 A T 1.18 1.95E-06 1.05 0.38 
rs4414254 11:5774814 T A 1.18 3.29E-06 1.03 0.68 
rs4597095 11:5775049 T C 1.18 3.54E-06 1.03 0.70 
rs5012841 11:5775730 C T 1.18 4.18E-06 1.02 0.75 
rs5012842 11:5775362 G A 1.18 4.17E-06 1.02 0.75 
rs5012843 11:5775360 C G 1.18 4.12E-06 1.02 0.75 
rs61875860 11:5773663 C T 1.18 2.72E-06 1.03 0.60 
rs61875861 11:5773735 C T 1.18 2.49E-06 1.04 0.58 
rs61875862 11:5773781 A T 1.18 2.66E-06 1.04 0.60 
rs7126020 11:5784187 T C 0.86 2.45E-06 1.05 0.63 
rs7395852 11:5777210 A G 0.86 3.08E-06 1.05 0.56 
a SNP position according to NCBI genome build 37 (Hg19) 








Supplementary Table 18 
Unconditional and conditional meta-analysis from 3 regions for oral cancer variants 
(P<5x10-8) at 2p23, conditioning was performed on the lead SNP rs6547741. Analyses 
adjusted by age, sex and eigenvectors. 
     Unconditional Conditional on rs6547741 




ORb P ORb P 
rs6547741 2:27855924 A G 0.8345 3.97E-08    
rs1528402 2:27857517 A G 0.8347 4.15E-08 3955.671 0.1828 
rs4666007 2:27856495 C T 0.8347 4.16E-08 145398.4 0.1004 
rs6547740 2:27854369 A G 0.8349 4.33E-08 0.0239 0.47 
a SNP position according to NCBI genome build 37 (Hg19) 
















Supplementary Table 19 
Unconditional and conditional meta-analysis from 3 regions for oral cancer variants at 
5p15.3, conditioning was performed on the lead SNP rs10462706 and rs467095. 
Analyses adjusted by age, sex and eigenvectors. 
 






ORb P ORb P conditioned on  
rs10462706 5:1343794 T C 0.74 5.54E-10 0.74 5.54E-10   
rs467095 5:1336221 C T 1.20 2.28E-08 1.13 5.14E-04 rs10462706 
rs112155367 5:1337070 G A 1.20 1.9E-08 1.16 1.16E-05 rs10462706 
rs201708486 5:1334508 I D 1.20 2.91E-08 1.16 1.58E-05 rs10462706 
rs2447853 5:1333077 G A 1.19 4.52E-08 1.15 1.92E-05 rs10462706 
rs31484 5:1337906 T A 1.20 3.68E-08 1.16 1.97E-05 rs10462706 
rs31487 5:1341101 C G 1.20 3.25E-08 1.16 1.46E-05 rs10462706 
rs31490 5:1344458 A G 1.20 3.6E-08 1.16 1.72E-05 rs10462706 
rs421284 5:1325590 G A 1.20 2.14E-08 1.16 9.88E-06 rs10462706 
rs452932 5:1330253 G A 1.19 4.31E-08 1.15 2.23E-05 rs10462706 
rs455433 5:1336243 G A 1.20 3.77E-08 1.16 2.01E-05 rs10462706 
rs459961 5:1337106 A T 1.19 4.52E-08 1.15 1.84E-05 rs10462706 
rs460073 5:1336459 G A 1.20 3.05E-08 1.16 1.69E-05 rs10462706 
rs10462706 5:1336221 C T 0.74 5.54E-10 0.78 4.24E-06 rs467095 
 
 a SNP position according to NCBI genome build 37 (Hg19) 











Supplementary Table 20 
Unconditional and conditional meta-analysis from 3 regions for oral cancer variants 
(P<5x10-8) at 9p21, conditioning was performed on the lead SNP lead rs8181047. 
Analyses adjusted by age, sex and eigenvectors. 
 
  









ORb P ORb P 
rs8181047 9:22064465 A G 1.24 3.80E-09 
 
  
rs10757268 9:22059905 C T 0.81 7.78E-09 1.03 0.87 
rs1412832 9:22077543 G A 1.23 1.34E-08 0.94 0.74 
rs1537378 9:22061614 A G 1.20 1.68E-07 1.04 0.51 
rs2095144 9:22060136 G A 0.81 6.93E-09 1.02 0.94 
rs2383205 9:22060935 A G 1.20 2.55E-07 1.05 0.43 
rs35307545 9:22071750 G A 1.19 1.65E-07 1.05 0.33 
rs3731239 9:21974218 G A 1.21 1.22E-08 1.11 0.03 
rs8181050 9:22064391 G A 1.20 1.74E-07 1.04 0.54 
rs944800 9:22050898 A G 1.21 7.42E-08 0.96 0.71 
a SNP position according to NCBI genome build 37 (Hg19) 










Supplementary Table 21 
Unconditional and conditional meta-analysis from 3 regions for oral cancer variants 
(P<5x10-8) at 9q34, conditioning was performed on the lead SNP lead rs928674. 
Analyses adjusted by age, sex and eigenvectors. 
        Unconditional 














rs928674 9:133952024 G A 1.33 2.09E-08 
 
  
rs10901348 9:133956465 A G 1.31 7.12E-08 
1.09 
0.47 
rs11791030 9:133971049 G T 1.31 1.68E-07 
1.09 
0.41 
rs199717881 9:133953882 C A 1.32 2.62E-08 
1.14 
0.32 
rs3765566 9:133942766 G A 1.31 2.28E-07 
1.01 
0.92 
rs72768533 9:133959518 G C 1.31 6.82E-08 
1.10 
0.40 
rs72768534 9:133959740 C G 1.31 6.77E-08 
1.10 
0.39 
rs73658919 9:133953983 G A 1.33 3.96E-08 
1.08 
0.68 
rs77452476 9:133962573 G T 1.29 5.97E-08 
1.13 
0.11 
rs7858204 9:133947345 A G 1.32 1.2E-07 
1.04 
0.79 
rs7875478 9:133947180 T A 1.32 1.23E-07 
1.04 
0.79 
a SNP position according to NCBI genome build 37 (Hg19) 















Supplementary Table 25 
Overall oral and pharyngeal analyses (6,034 cases and 6,585 controls) top loci stratified 
analyses (region, rumor site, gender, tobacco smoking and alcohol drinking status). Data for 
forest plots in Figure 2. 
a. rs1229984 4q23 case control OR P 95% CI 
Region Europe 2490 2905 0.50 9.74E-10 0.40 0.62 
 North America 2541 2503 0.74 9.59E-03 0.59 0.93 
 South America 977 1116 0.38 3.21E-08 0.27 0.53 
Site Oral 2975 6524 0.57 1.09E-09 0.48 0.68 
 Oropharynx 2632 6524 0.55 8.53E-09 0.45 0.67 
Gender Men 4506 4283 0.51 2.64E-14 0.43 0.60 
 Women 1501 2241 0.70 8.57E-03 0.53 0.91 
Smoking Status Never 1052 2483 0.93 5.87E-01 0.72 1.20 
 Former 1780 2244 0.71 8.70E-03 0.55 0.92 
 Current 2615 1451 0.33 5.76E-15 0.25 0.43 
Drinking Status Never 816 1183 0.63 1.67E-04 0.50 0.80 
 Ever 4820 4797 0.49 1.36E-15 0.42 0.58 
 
b. rs201982221 10q26.13 case control OR P 
95% CI 
  
Region Europe 2462 2910 1.87 1.16E-06 1.46 2.42 
  North America 2531 2504 1.53 8.81E-04 1.19 1.96 
  South America 982 1129 1.55 7.85E-02 0.95 2.51 
Site Oral 2961 6543 1.71 1.05E-07 1.41 2.08 
  Oropharynx 2613 6543 1.70 7.98E-07 1.38 2.09 
  Men 4484 4299 1.66 1.31E-06 1.35 2.03 
  Women 1490 2244 1.81 1.05E-04 1.34 2.43 
Smoking Status Never 1049 2494 1.17 2.83E-03 1.19 2.32 
  Former 1768 2251 1.35 6.02E-03 1.13 2.09 
  Current 2597 1452 1.32 1.72E-02 1.07 2.03 
Drinking Status Never 814 1189 1.63 3.07E-04 1.25 2.13 
  Ever 4789 4809 1.60 1.43E-06 1.33 1.93 
 
c. rs1453414 11p15 case control OR P 95% CI 
Region Europe 2493 2915 1.22 1.56E-04 1.10 1.35 
  North America 2541 2509 1.21 1.16E-04 1.10 1.34 
  South America 983 1129 1.11 1.80E-01 0.95 1.29 
Site Oral 2981 6553 1.19 1.65E-05 1.10 1.28 
  Oropharynx 2635 6553 1.22 4.26E-06 1.12 1.32 
Gender Men 4514 4307 1.18 2.29E-05 1.09 1.27 
  Women 1502 2246 1.24 3.47E-04 1.10 1.40 
Smoking Status Never 1053 2498 1.17 2.24E-02 1.02 1.33 
  Former 1785 2248 1.33 1.75E-06 1.18 1.49 
  Current 2617 1461 1.18 6.80E-03 1.05 1.34 
Drinking Status Never 819 1193 1.11 5.03E-02 1.00 1.23 
  Ever 4825 4817 1.19 2.92E-06 1.11 1.28 
 
 
 d. rs3828805 6p21.32 case control OR P 95% CI 
Region Europe 2499 2928 1.39 6.09E-09 1.24 1.56 
  North America 2549 2522 1.30 8.63E-08 1.18 1.43 
  South America 986 1135 1.04 6.18E-01 0.89 1.21 
Site Oral 2990 6585 1.23 2.83E-07 1.14 1.34 
  Oropharynx 2641 6585 1.37 2.21E-12 1.25 1.50 
Gender Men 4527 4325 1.31 8.38E-12 1.22 1.42 
  Women 1507 2260 1.22 1.43E-03 1.08 1.38 
Smoking Status Never 1057 2508 1.32 1.30E-02 1.06 1.65 
  Former 1792 2263 1.36 5.28E-07 1.20 1.53 
Drinking Status Current 2623 1466 1.27 1.07E-04 1.13 1.44 
  Never 820 1199 1.17 8.55E-02 0.98 1.39 






























Supplementary Table 26 
Oral analyses (2,990 cases and 6,585 controls) top loci stratified analyses (region, gender, 
tobacco smoking and alcohol drinking status). Data for forest plots in Figure 3. 
a. rs6547741 2p23 case control OR P 95% CI 
Region Europe 1225 2928 0.84 6.46E-04 0.76 0.93 
  North America 1238 2522 0.80 1.03E-05 0.72 0.88 
  South America 527 1135 0.92 2.64E-01 0.79 1.07 
Gender Men 2045 4325 0.84 9.42E-06 0.77 0.90 
  Women 945 2260 0.84 2.81E-03 0.75 0.94 
Smoking Status Never 543 2508 0.87 5.89E-02 0.76 1.01 
  Former 815 2263 0.79 1.19E-04 0.69 0.89 
Drinking Status Current 1410 1466 0.81 2.84E-04 0.72 0.91 
  Never 469 1199 0.86 8.18E-02 0.72 1.02 
  Ever 2369 4840 0.82 2.62E-07 0.77 0.89 
 
b. s10462706 5p15.3 case control OR P 95% CI 
Region Europe 1225 2928 0.75 1.87E-04 0.65 0.87 
  North America 1238 2522 0.74 7.04E-05 0.63 0.86 
  South America 527 1135 0.69 2.62E-03 0.55 0.88 
Gender Men 2045 4325 0.74 7.64E-07 0.66 0.84 
  Women 945 2260 0.71 1.44E-04 0.60 0.85 
Smoking Status Never 543 2508 0.60 7.27E-06 0.48 0.75 
  Former 815 2263 0.71 3.98E-04 0.59 0.86 
Drinking Status Current 1410 1466 0.83 3.48E-02 0.70 0.99 
  Never 469 1199 0.53 2.02E-06 0.41 0.69 
  Ever 2369 4840 0.76 1.21E-06 0.68 0.85 
 
c. rs8181047 9p21.3 case control OR P 95% CI 
Region Europe 1225 2926 1.18 2.28E-03 1.06 1.32 
  North America 1237 2522 1.25 7.27E-05 1.12 1.39 
  South America 527 1135 1.39 7.01E-04 1.15 1.68 
Gender Men 2044 4324 1.25 5.96E-07 1.15 1.37 
  Women 945 2259 1.21 2.84E-03 1.07 1.37 
Smoking Status Never 543 2507 1.25 3.40E-03 1.08 1.46 
  Former 814 2262 1.17 2.10E-02 1.02 1.34 
Drinking Status Current 1410 1466 1.36 4.50E-06 1.19 1.55 
  Never 469 1199 1.29 9.34E-03 1.06 1.55 
  Ever 2368 4839 1.24 3.54E-07 1.14 1.34 
 
d. rs928674 9q34   case control OR P 95% CI 
Region Europe 1225 2928 1.31 6.48E-04 1.12 1.53 
  North America 1238 2522 1.36 5.63E-05 1.17 1.58 
  South America 527 1135 1.27 5.07E-02 1.00 1.62 
Gender Men 2045 4325 1.33 4.92E-06 1.18 1.50 
  Women 945 2260 1.30 3.09E-03 1.09 1.55 
Smoking Status Never 543 2508 1.32 1.30E-02 1.06 1.65 
  Former 815 2263 1.45 6.81E-05 1.21 1.73 
Drinking Status Current 1410 1466 1.38 4.00E-04 1.16 1.66 
  Never 469 1199 1.43 7.18E-03 1.10 1.85 
  Ever 2369 4840 1.33 9.94E-07 1.18 1.49 
 
